- Conditions
- Optic Neuritis
- Interventions
- Efgartigimod Alfa, Placebo
- Drug
- Lead sponsor
- Anastasia Vishnevetsky, MD, MPH
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 3,857
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Sclerosis (MS)
- Interventions
- H.P. Acthar Gel (repository corticotropin injection)
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 2
- States / cities
- Oceanside, California • Houston, Texas
- Conditions
- Systemic Sclerosis
- Interventions
- RO7303509, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 3
- States / cities
- Palo Alto, California • New York, New York • Dallas, Texas
- Conditions
- Atopic Dermatitis
- Interventions
- FB825 or Placebo in subcutaneous route, FB825 in intravenous route
- Drug
- Lead sponsor
- Oneness Biotech Co., Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Anaheim, California
- Conditions
- Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML)
- Interventions
- WT1:126-134, PR1:169-177 Peptide, GM-CSF (Sargramostim), Montanide adjuvant
- Biological · Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Smoking Cessation, Smoking Behaviors
- Interventions
- Tirzepatide, Placebo
- Drug · Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 1 more
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Interventions
- Itepekimab (SAR440340), Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- La Mesa, California • Oklahoma City, Oklahoma • Fort Worth, Texas
- Conditions
- Carcinoma, Non-small-Cell Lung
- Interventions
- Amivantamab, Lazertinib, Carboplatin, Pemetrexed, Direct Oral Anticoagulant (DOAC), Low Molecular Weight Heparin (LMWH)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 26
- States / cities
- La Jolla, California • Orange, California • Stanford, California + 21 more
- Conditions
- Heart Failure, Fluid Overload
- Interventions
- SCP-111, Furosemide USP
- Drug
- Lead sponsor
- scPharmaceuticals, Inc.
- Industry
- Eligibility
- 45 Years to 80 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Autoimmune Hepatitis
- Interventions
- Orencia® (Abatacept)
- Drug
- Lead sponsor
- Stuart Knechtle, M.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Colitis, Ulcerative
- Interventions
- LY3471851, Placebo
- Drug
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 7
- States / cities
- Litchfield Park, Arizona • Kissimmee, Florida • Pensacola, Florida + 4 more
- Conditions
- Pharmacokinetics of ASP2408, Healthy Subjects
- Interventions
- ASP2408, Placebo
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- HIV Infections
- Interventions
- Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed, Diphtheria and Tetanus Toxoids Adsorbed, Tetanus and Diphtheria Toxoids Adsorbed, Bacteriophage phi X 174, Aldesleukin
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2006
- U.S. locations
- 13
- States / cities
- Long Beach, California • Los Angeles, California • San Diego, California + 8 more
- Conditions
- Hepatitis C
- Interventions
- Locteron (controlled-release interferon alpha 2b), pegylated IFNa2b
- Other · Biological
- Lead sponsor
- Biolex Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 5
- States / cities
- Detroit, Michigan • Dallas, Texas • San Antonio, Texas + 2 more
- Conditions
- Melanoma
- Interventions
- Vidutolimod (CMP-001), Nivolumab, [18F]F-AraG PET/CT
- Drug · Biological · Other
- Lead sponsor
- Diwakar Davar
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Crohn's Disease
- Interventions
- Andecaliximab, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 33
- States / cities
- Dothan, Alabama • Scottsdale, Arizona • Los Angeles, California + 30 more
- Conditions
- Chronic Myeloid Leukemia
- Interventions
- Dasatinib, Ropeginterferon alfa-2b (P1101)
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Atopic Dermatitis
- Interventions
- Tralokinumab, Placebo
- Drug
- Lead sponsor
- LEO Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Encinitas, California • Fountain Valley, California + 17 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- LY2428757, TT223, Placebo for LY2428757, Placebo for TT223
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Anaheim, California • Artesia, California + 23 more
- Conditions
- Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma, Other Plasma Cell Dyscrasia (Waldenstrom, Amyloidosis), Leukemia
- Interventions
- GM-CSF, IL-2
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Rheumatoid Arthritis
- Interventions
- Veltuzumab
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 8
- States / cities
- La Mesa, California • Los Angeles, California • Upland, California + 5 more
- Conditions
- Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS)
- Interventions
- Ivosidenib, Azacitidine
- Drug
- Lead sponsor
- Institut de Recherches Internationales Servier
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 9
- States / cities
- Denver, Colorado • Chicago, Illinois • Boston, Massachusetts + 6 more
- Conditions
- Obesity
- Interventions
- PF-07081532, Semaglutide
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Anaheim, California
- Conditions
- Hypertension, Pulmonary
- Interventions
- Sotatercept
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2035
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • La Jolla, California • Santa Barbara, California + 20 more